The Cancer Therapeutics Program (CRX) is designed to advance translation of discoveries to the clinic. CRX brings together all investigator-initiated clinical trials (Aim 3) as well as preclinical development of cancer immunology and immunotherapy (Aim 1) and cancer imaging, drug delivery, and image-based technologies (Aim 2).
Key goals of CRX are to identify promising new discoveries and technologies and then to support collaborations and other opportunities to bring these technologies to clinical trials, licensing, and clinical development. The ultimate goal of this program is to reduce the burden of cancer in the catchment area and beyond, especially for cancers of high incidence or mortality in the catchment area (breast, colorectal, lung, and melanoma).
Goals of this aim are to advance understanding of cellular interactions in tumor microenvironments that are crucial for the success of immune therapies and to develop new immunotherapy agents, including adoptive cellular therapies, bispecific antibodies, and combinations of immune modulators. The work of this aim is enhanced by new recruitments, investment in adoptive cell therapy, and a new cGMP facility.
Investigators in this aim are developing innovative approaches to deliver cancer therapies more effectively while reducing toxicity. These include engineering new materials to encapsulate small molecule drugs; developing image-guided therapies, such as focused ultrasound, for more effective drug delivery to cancers; and using imaging to guide therapy, interrogate systemic drug response, and drive patient treatment selection.
The CRX program’s co-leads offer expertise in nanoparticle techniques for diagnostic imaging, drug target identification and drug delivery, as well as neuroimmunology and novel therapeutic approaches to brain cancers.